Loading
companiesCompany
Haihe Biopharma
Haihe Biopharma is a China-based biotechnology company running 4 late-stage cancer trials of HH2853, Glumetinib and CYH33 in non-small-cell lung cancer, follicular lymphoma and sarcomas.
Also called: Haihe Biopharma Co., Ltd.
Overview
Haihe Biopharma, based in Shanghai, China, is a biotechnology company. Haihe Biopharma (Shanghai Haihe Pharmaceuticals) is a China-based biopharmaceutical company focused on the discovery, development, production and commercialisation of innovative drugs, including several oncology candidates. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing HH2853, Glumetinib and CYH33 in non-small-cell lung cancer, follicular lymphoma, sarcomas, peripheral T-cell lymphomas and hodgkin lymphoma. The largest, NCT04390737 (Evaluate the Safety and Clinical Activity of HH2853), plans to enrol 254 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#258of 1244 companies, score 19
- approved products +6
- phase 1/2 +1
- targets +2
- modalities +2
- regions +1
- registry trials +7
1 approved, 0 in phase 3, 1 earlier, 1 targets, 11 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2011
Phase 2Small-molecule inhibitor
CYH33 is a small-molecule inhibitor from Haihe Biopharma Co., Ltd., in registered phase 2 trials for ovarian cancer.
ApprovedOral selective MET tyrosine kinase inhibitor
Glumetinib is a Chinese MET inhibitor approved in 2023 for lung cancers with MET exon 14 skipping, one of three such drugs approved in China and now in a phase 3 trial in gastric cancer.
Similar pages
- CollectionLymphoma Research Foundation (LRF)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- TrialA Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N
Shares Glumetinib, Non-small-cell lung cancer.
- InstitutionLymphoma Action
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- InstitutionAnthony Nolan
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- CancerClear cell ovarian cancer
Shares A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma, Ovarian cancer.
- TermVaccinations around lymphoma treatment: the ones to have first, and the ones not to have at all
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- InstitutionBlood Cancer UK
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- CompanyEvopoint Biosciences
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma, Ovarian cancer.
cancers
drugs
Phase 2Small-molecule inhibitor
ApprovedOral selective MET tyrosine kinase inhibitor
trials
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell CarcinomaAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerEvaluate the Safety and Clinical Activity of HH2853Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma